MX9800186A - Derivados de azetidinona para el tratamiento de ateroesclerosis. - Google Patents

Derivados de azetidinona para el tratamiento de ateroesclerosis.

Info

Publication number
MX9800186A
MX9800186A MX9800186A MX9800186A MX9800186A MX 9800186 A MX9800186 A MX 9800186A MX 9800186 A MX9800186 A MX 9800186A MX 9800186 A MX9800186 A MX 9800186A MX 9800186 A MX9800186 A MX 9800186A
Authority
MX
Mexico
Prior art keywords
alkyl
aryl
heteroaryl
optionally substituted
atherosclerosis
Prior art date
Application number
MX9800186A
Other languages
English (en)
Inventor
Dashyant Dhanak
Deirdre Mary Bernadette Hickey
Robert John Ife
Colin Andrew Leach
David Graham Tew
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9513442.5A external-priority patent/GB9513442D0/en
Priority claimed from GBGB9515056.1A external-priority patent/GB9515056D0/en
Priority claimed from GBGB9515206.2A external-priority patent/GB9515206D0/en
Priority claimed from GBGB9516985.0A external-priority patent/GB9516985D0/en
Priority claimed from GBGB9525132.8A external-priority patent/GB9525132D0/en
Priority claimed from GBGB9608650.9A external-priority patent/GB9608650D0/en
Priority claimed from GBGB9608651.7A external-priority patent/GB9608651D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MX9800186A publication Critical patent/MX9800186A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de azetidinona de la formula: (Ver Formula) en la cual R1 y R2, que pueden ser los mismos o diferentes, seleccionan cada uno de hidrogeno, halogeno o alquilo de C1-8; R4 y R6, que pueden ser los mismos o diferentes, se seleccionan cada uno de hidrogeno, alquilo de C1-6, alquenilo de C2-6, arilo arilalquilo de C1-4 y heteroarilalquilo de C1-4, cada uno de los cuales puede estar substituido opcionalmente, o R4 y R5 pueden estar unidos entre si para formar el resto de un anillo de cicloalquilo de C3-7; X es un grupo de enlace; Y es grupo arilo substituido opcionalmente; Z es oxígeno y R3 es alquilo de C1-8, cicloalquilo de C4-8, cicloalquil(3-8)-alquilo de C1-C6, heteroarilo, heteroarilalquilo de C1-4, arilo o arilalquilo de C1-4, cada uno de los cuales puede estar substituido opcionalmente, o Z es 5(0)n, en la cual n es 0, 1 o 2, y R3 es alquilo de C1-8, cicloalquilo de C3-8, cicloalquil(C3-8)-alquilo de C1-6, arilo, arilalquilo de C1-4, heteroarilo o heteroarilalquilo de C1-4, cada uno de los cuales puede estar substituido opcionalmente, son inhibidores de la enzima Lp-PLA2 y se usan en terapia, en particular el tratamiento de ateroesclerosis.
MX9800186A 1995-07-01 1998-01-07 Derivados de azetidinona para el tratamiento de ateroesclerosis. MX9800186A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9513442.5A GB9513442D0 (en) 1995-07-01 1995-07-01 Novel compounds
GBGB9515056.1A GB9515056D0 (en) 1995-07-22 1995-07-22 Novel compounds
GBGB9515206.2A GB9515206D0 (en) 1995-07-25 1995-07-25 Novel compounds
GBGB9516985.0A GB9516985D0 (en) 1995-08-18 1995-08-18 Novel compounds
GBGB9525132.8A GB9525132D0 (en) 1995-12-08 1995-12-08 Novel compounds
GBGB9608650.9A GB9608650D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9608651.7A GB9608651D0 (en) 1996-04-26 1996-04-26 Novel compounds

Publications (1)

Publication Number Publication Date
MX9800186A true MX9800186A (es) 1998-07-31

Family

ID=27562921

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800186A MX9800186A (es) 1995-07-01 1998-01-07 Derivados de azetidinona para el tratamiento de ateroesclerosis.

Country Status (23)

Country Link
EP (1) EP0840725A1 (es)
JP (1) JP2002515852A (es)
KR (1) KR19990028630A (es)
CN (1) CN1197452A (es)
AP (1) AP728A (es)
AU (1) AU708032B2 (es)
BG (1) BG102214A (es)
BR (1) BR9609445A (es)
CA (1) CA2225627A1 (es)
CZ (1) CZ422197A3 (es)
EA (1) EA199800109A1 (es)
HU (1) HUP9901153A3 (es)
IL (1) IL122650A0 (es)
MA (1) MA23922A1 (es)
MX (1) MX9800186A (es)
NO (1) NO976158L (es)
NZ (1) NZ311684A (es)
OA (1) OA10648A (es)
PE (1) PE8998A1 (es)
PL (1) PL324240A1 (es)
SK (1) SK178497A3 (es)
TR (1) TR199701762T1 (es)
WO (1) WO1997002242A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502079A (ja) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
GB9608649D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
HUP9901359A3 (en) * 1996-04-26 2000-03-28 Smithkline Beecham Plc Azetidinone derivatives for the treatment of atherosclerosis, process for their producing and pharmaceutical compositions containing them
AU3546601A (en) 2000-02-16 2001-08-27 Smithkline Beecham Plc Pyrimidine-4-one derivatives as LDL-PLA<sub>2</sub> inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
MX2009012197A (es) 2007-05-11 2010-01-15 Univ Pennsylvania Metodos para tratamiento de ulceras en la piel.
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
EP2977452A3 (en) 2007-05-11 2016-05-25 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
MX2013006342A (es) 2010-12-06 2013-08-26 Glaxo Group Ltd Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2).
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
US20140171431A1 (en) 2011-06-27 2014-06-19 Jianhua Shen Azole heterocyclic compound, preparation method, pharmaceutical composition and use
WO2013013503A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
EP2736908A1 (en) 2011-07-27 2014-06-04 Glaxo Group Limited Bicyclic pyrimidone compounds
CN105008365B (zh) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 化合物
SG11201505520WA (en) 2013-01-25 2015-08-28 Glaxosmithkline Ip Dev Ltd 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS
EP2948456A4 (en) 2013-01-25 2016-09-14 Glaxosmithkline Ip Dev Ltd BICYCLIC PYRIMIDONE COMPOUNDS AS LP-PLA2 INHIBITORS
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
AU2020379796C1 (en) 2019-11-09 2024-05-02 Shanghai SIMR Biotechnology Co., Ltd Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
CA2208530A1 (en) * 1994-12-22 1996-06-27 Smithkline Beecham P.L.C. Substituted azetidin-2-ones for treatment of atherosclerosis

Also Published As

Publication number Publication date
NO976158D0 (no) 1997-12-30
EP0840725A1 (en) 1998-05-13
AU708032B2 (en) 1999-07-29
IL122650A0 (en) 1998-08-16
JP2002515852A (ja) 2002-05-28
NZ311684A (en) 2000-04-28
TR199701762T1 (xx) 1998-05-21
NO976158L (no) 1998-02-25
HUP9901153A3 (en) 1999-11-29
AP728A (en) 1999-01-29
BR9609445A (pt) 1999-04-06
AU6305096A (en) 1997-02-05
KR19990028630A (ko) 1999-04-15
SK178497A3 (en) 1998-07-08
BG102214A (en) 1998-08-31
WO1997002242A1 (en) 1997-01-23
MA23922A1 (fr) 1996-12-31
PL324240A1 (en) 1998-05-11
OA10648A (en) 2002-09-25
CZ422197A3 (cs) 1998-06-17
CN1197452A (zh) 1998-10-28
CA2225627A1 (en) 1997-01-23
PE8998A1 (es) 1998-03-20
HUP9901153A2 (hu) 1999-08-30
AP9701161A0 (en) 1998-01-31
EA199800109A1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
MX9800186A (es) Derivados de azetidinona para el tratamiento de ateroesclerosis.
MX9704736A (es) Acetidin 2-onas sustituidas, procedimiento para prepararlas, uso de las mismas y composiciones que las contienen.
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
MY120090A (en) Chemical compounds.
HK1016177A1 (en) New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
DE69831937D1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
MX9707453A (es) Derivados de quinazolina.
MX9700430A (es) El uso de compuestos heterociclicos.
DE69719350D1 (de) 2-pyrimidinamin derivaten und verfahrens zu deren herstellung
DK0889886T3 (da) Hidtil ukendte, i 6-stilling substituerede phenanthridiner
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
TR199800011T1 (xx) Benzo$g] kuinolin t�revleri
MX9701685A (es) Nuevos derivados de bencimidazol que tienen la actividad de inhibicion de la fosfodiestearasa cgmp.
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
DE69833797D1 (de) Substituierte 2-benzylamino-2-phenyl-acetamidverbindungen
MX9800412A (es) Preparacion de 3-hidroxipirazoles n-substituidos.
ATE233741T1 (de) Antivirale 2,4-pyrimidindion-derivate und verfahren zu ihrer herstellung
HK1014011A1 (en) Cyclopeptolides
TR200003877T2 (tr) İnsan CD23 üretiminin ve TNF salınmasının ihhibitörleri olan hiydroxamic acid türevleri
NO990436L (no) FremgangsmÕte for behandling av bipolar forstyrrelse
AU758194C (en) Novel benzimidazoles and benzoxazoles
ATE227718T1 (de) N-aryloxyethyl-indolyl-alkylamine zur behandlung von depressionen
MX9700125A (es) Compuestos de pirimidina.
ATE263139T1 (de) 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie